Oramed (NASDAQ: ORMP) CEO receives 167,005 RSUs vesting from 2026

Rhea-AI Filing Summary

KIDRON NADAV reported acquisition or exercise transactions in this Form 4 filing.

Oramed Pharmaceuticals reported that President and CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units (RSUs) of common stock at no cash cost. The award increases his direct holdings to 3,422,243 shares after the transaction.

The RSUs will vest in eight equal quarterly installments beginning April 1, 2026, aligning a portion of the CEO’s compensation with the company’s long-term performance. Each RSU represents the right to receive one share of Oramed common stock as it vests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIDRON NADAV

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		A		167,005(1)	A	$0(1)	3,422,243	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.

	/s/ Nadav Kidron	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Oramed (ORMP) disclose for Nadav Kidron?

Oramed disclosed that CEO Nadav Kidron received 167,005 RSUs. These restricted stock units were granted at no cash cost and represent future rights to common shares, increasing his equity-based compensation and tying part of his pay to Oramed’s long-term share performance.

How many Oramed (ORMP) shares does the CEO hold after this Form 4?

After the RSU grant, CEO Nadav Kidron holds 3,422,243 shares directly. This total includes the newly awarded 167,005 restricted stock units, which convert into common shares as they vest over time under the disclosed vesting schedule.

What is the vesting schedule for Nadav Kidron’s 167,005 Oramed RSUs?

The 167,005 RSUs will vest in eight equal quarterly installments starting April 1, 2026. Each quarter, one-eighth of the award becomes vested, gradually delivering common shares to the CEO over a two-year period, subject to continued service and plan terms.

What does each Oramed (ORMP) RSU granted to the CEO represent?

Each RSU represents the right to receive one share of Oramed common stock. As the RSUs vest according to the quarterly schedule beginning April 1, 2026, they convert into actual shares with par value $0.012 per share, increasing the CEO’s owned stock.

Was Nadav Kidron’s Oramed RSU grant an open-market stock purchase?

No, the transaction is classified as a grant or award, not an open-market purchase. The Form 4 uses transaction code “A,” indicating a compensatory equity award of RSUs at zero price rather than a cash-funded buy in the public market.